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Background The Australian Therapeutic Guidelines does not endorse culture and susceptibility testing prior to salvage 
therapy for Helicobacter pylori eradication.  We wished to determine whether this remains appropriate. 
Aim To determine the sensitivity (as minimum inhibitory concentrations, MIC) of H pylori to a range of antibiotics used in 
salvage therapy over time. 
Methods From 2012 to 2017, gastric or duodenal biopsy samples were obtained from 154 patients receiving H pylori 
eradication therapy.  MIC for amoxicillin, clarithromycin, tetracycline, metronidazole, rifampicin and levofloxacin were 
measured using standard laboratory techniques. 
Results A significant increase from zero to 28% in secondary resistance to levofloxacin amongst H. pylori in Western 
Australia was noted over the study period.  No corresponding trend was seen with the other antibiotics. 
Conclusions These findings suggest that selective use of culture and susceptibility testing may be warranted prior to 





The prevalence of H pylori (HP) in Australian 
populations varies between the non-indigenous 
(15.4 - 30.6%), indigenous (76%) and migrant 
populations (46.2 - 91%).1-3 HP eradication therapy 
has a role in the management of peptic ulcer 
disease, non-ulcer dyspepsia, gastric cancer and 
mucosa-associated lymphoid tissue lymphoma.4-6  
Selection of first-line and salvage HP eradication 
therapy is guided by local surveillance studies as 
both primary (obtained from patients without prior 
HP eradication therapy) and secondary (obtained 
from patients with at least one course of prior HP 
eradication therapy) isolate resistance demonstrates 
significant global geographical variation.7,8 The 
Australian Therapeutic Guidelines endorses the 
combination of clarithromycin, amoxicillin and a 
proton pump inhibitor as first-line eradication 
therapy, based upon local susceptibility data. In the 
event of treatment failure, salvage therapies include 
a fluoroquinolone (most commonly levofloxacin), 
rifabutin-based triple therapy or tetracycline-based 
quadruple therapy.9 Historically low rates of 
resistance to all three of these classes of 





selection has not required prior culture and 
susceptibility testing.4,9 
 
We wished to determine the local (Western 
Australia) prevalence, including temporal trends, of 
secondary resistance amongst HP, and to identify 
host risk factors for fluoroquinolone resistance.  
 
Methods 
We performed a prospective cohort study from 
2012 to 2017.  This included all patients who had 
received at least one course of HP eradication 
therapy, and from whom a HP isolate was 
subsequently cultured from gastric and/or duodenal 
biopsy specimens.  The material was processed by 
the Microbiology Department of PathWest 
Laboratory Medicine (PathWest, Perth WA) at the 
Royal Perth Hospital (RPH).  RPH is a tertiary 
metropolitan public teaching hospital in Perth, 
Western Australia. 
 
Cases were identified on the basis of the laboratory 
log of all isolates for which susceptibility testing 
was performed. Specimen processing and 
susceptibility testing utilised standardised 
laboratory methods.12 The MIC for amoxicillin, 
clarithromycin, tetracycline, metronidazole, 
rifampicin and levofloxacin were determined using 
Etests according to the manufacturer’s instructions 
(AB Biodisk, Sweden) and interpreted using 
European Committee on Antimicrobial 
Susceptibility Testing susceptibility breakpoints.13  
 
For patients harbouring fluoroquinolone-resistant 
isolates, patient demographics and details of prior 
HP eradication therapy were extracted 
retrospectively from patient medical records. For 
the purposes of comparison, the same information 
was extracted for twice as many randomly selected 




Comparison of demographic variables between 
groups was assessed by chi-squared test for 
categorical variables. All statistical analysis was 
done using SPSS software (v25) and p < 0.05 was 
considered significant. Ethics approval was 
obtained from the East Metropolitan Health Human 




The study cohort consisted of 154 patients with a 
median age of 45 years (interquartile range 37-58), 
of whom 49% were male. Their regions of birth 
were Australia (n=64, 41.5%), Asia (n=63, 40.9%), 
Europe (n=11, 7%), Africa (n=9, 5.8%), Middle 
East (n=6, 3.8%) and North America (n=1, 0.6%).  
 
Table 1 provides the rates of HP isolates with 
secondary resistance to differing antimicrobial 
classes. There was a significant temporal increase 
in resistance of HP to levofloxacin from 2012 to 
2017 when expressed as the percentage of all 
isolates with each class of antimicrobial (p < 
0.001). As similar trend was not observed with 
other antimicrobial classes but a late increase in 
resistance for rifampicin was noted.  The MIC50 
and MIC90 for levofloxacin over the study period 
were 0.064 and 4 microg/mL respectively.   
 
Rates of levofloxacin resistance were significantly 
higher in those born outside of Australia (20/90, 
22.2 %) compared to those born within Australia 
(0/64, 0%; p<0.001). The countries of birth of 
patients with levofloxacin resistant isolates were 
China (7), India (3), Russia (2), Afghanistan (2), 
Vietnam (2), Iran (2), Korea (1) and Sudan (1). 
 
Prior exposure to fluoroquinolones occurred in 13 
(65%) of 20 patients with levofloxacin resistant 
isolates, compared to 5 (12.5%) of 40 patients with 
levofloxacin susceptible isolates (OR 15.17, 95% 
CI, 3.9–58.3, p<0.001).  Multivariate analysis 
showed that prior fluoroquinolone use and being 
born overseas were co-variates (p = 0.024). 
 
Discussion 
Our study demonstrates that in a collection of 
Western Australian HP isolates, secondary 
resistance to fluoroquinolones increased 
progressively from zero to 27.8% from 2012-2017 
(Table 1). This trend may be driven by an 
increasing number of isolates obtained from 
patients born overseas.  This is a novel risk factor 
for fluoroquinolone-resistant Helicobactor pylori. 
 
Systematic antimicrobial susceptibility surveillance 
programs exist in Australia and New Zealand for a 




 Secondary resistance rates [% of year total, (number)] 
Year Cases Amoxicillin Clarithromycin Metronidazole Tetracycline Rifampicin Levofloxacin 
2012 10 0% (0) 90% (9) 90% (9) 0% (0) 0% (0) 0% (0) 
2013  24 0% (0) 100% (24) 70% (17) 0% (0) 17% (4) 4% (1) 
2014  20 0% (0) 70% (14) 65% (13) 0% (0) 15% (3) 5% (1) 
2015  30 0% (0) 93% (28) 70% (21) 3% (1) 20% (6) 7% (2) 
2016  34 3% (1) 94% (32) 77% (26) 6% (2) 18% (6) 18% (6) 
2017  36 0% (0) 94% (34) 67% (24) 0% (0) 25% (9) 28% (10) 
Total  154 <1% (1) 91% (141) 71% (110) 2% (3) 18% (28) 13% (20) 




programs do not include HP.14  We are aware of 
only 1 previous Australian study of secondary 
resistance to fluoroquinolones.15  Seven years ago, 
Tay et al found a rate of secondary resistance to 
fluoroquinolones of 6%, but no attempt was made 
to examine temporal trends or risk factors for 
harbouring fluoroquinolone resistant isolates. 
 
Increasing rates of fluoroquinolone resistant HP are 
well described overseas.10,16,17 However, in contrast 
to the Australian setting, this has largely been 
attributed to increased rates of primary resistance,10 
which in turn correlates with increased community 
consumption of fluoroquinolones.18 Due to a policy 
of restricted access, the Australian community 
experiences uniquely low usage of 
fluoroquinolones,14 which is reflected in a recent 
Australian study demonstrated nil primary 
fluoroquinolone resistance with HP.19  
 
Several factors may explain increasing secondary 
resistance to fluoroquinolones in Australia.  Firstly, 
immigration to Australia from neighbouring 
developing countries, in which there are higher 
rates of fluoroquinolone resistant HP, is 
increasing1,15,20 and importation of fluoroquinolone 
resistant pathogens other than HP has previously 
been described.21,22 As has occurred overseas,16,18,23 
increased use of fluoroquinolone-based salvage 
therapy is likely to be occurring in Australia as, 
during the study period, more recent versions of the 
national guidelines endorsed fluoroquinolone-based 
salvage regimes9 and levofloxacin availability 
increased.9 Following fluoroquinolone exposure, 
stepwise point mutations within the gyrA and gyrB 
regions leads to an incremental increase in 
fluoroquinolone MIC24 and prior fluoroquinolone 
therapy has previously been shown to be a risk 
factor for resistance to this class of 
antimicrobial.18,25  Prior non-fluoroquinolone 
therapy also been shown to be a risk factor for 
fluoroquinolone resistance in HP, possibly due to 
co-selection of fluoroquinolone resistance 
determinants.26 
 
Our findings have important clinical implications. 
Currently empiric fluoroquinolone-based salvage 
therapy without prior biopsy for culture and 
susceptibility testing is endorsed by the Australian 
Therapeutic Guidelines.9  The major determinant of 
successful HP eradication is the absence of pre-
treatment resistance27 and a recent international 
consensus statement4 proposed that when 
clarithromycin resistance rates exceed 15-20%, this 
class of antimicrobial should not constitute part of 
empirical HP eradication therapy. By extension, 
our data suggests that, for a subset of patients 
receiving salvage therapy, fluoroquinolone 
resistance may have exceeded this threshold in 
Western Australia.  Thus we believe there may be a 
role for selective culture and antimicrobial 
susceptibility testing to guide choice of salvage 
therapy. In the context of HP demonstrating 12% 
secondary resistance to fluoroquinolones, a recent 
Italian randomised controlled trial demonstrated 
this strategy to be associated with significantly 
higher rates of HP eradication.28 It may also be 





others data, patients who would benefit from this 
strategy could be identified based upon risk factors 
for fluoroquinolone resistance such as country of 
residence7,10,18 or birth, prior fluoroquinolone-based 
HP eradication therapy and increasing age.5,25 
 
Throughout the study we demonstrated low rates of 
resistance to amoxicillin, indicating that it remains 
an appropriate component of fluoroquinolone-
based salvage regimes. In the event that non-
fluoroquinolone based salvage therapy is 
warranted, isolates are (on the basis of our data) 
more likely to be susceptible to tetracycline than 
rifampicin, while acknowledging that rifampicin 
resistant does not necessarily predict rifabutin 
resistance.31  
 
Our study has several other limitations. Being a 
tertiary hospital laboratory, there may be a 
selection bias towards more resistant isolates. HP 
susceptibility profiles are geographically disparate 
which may limit the generalisability of our data, 
and emphasises the need for periodic local 
surveillance to inform therapeutic guidelines. We 
did not analyse clinical outcomes and hence we 
were unable determine the in vivo impact of 
fluoroquinolone resistance. We note that 
fluoroquinolone-based salvage therapy demon-
strated 90% HP eradication success rate in the 
Australian context, although secondary resistance 
rates were not assessed.19 
 
Conclusions 
Our study demonstrates that, as with other 
pathogens in Australia and overseas,14 rates of 
antimicrobial resistance in HP continue to rise, 
which has implications for selection of empiric 
salvage therapy. There may be an increased need 
for selective culture and susceptibility testing, 
performed on patients selected based upon risk 
factors such as prior fluoroquinolone therapy and 
country of birth.  
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